The Role of Anti-HLA Antibodies in Hematopoietic Stem Cell Transplantation  by Focosi, Daniele et al.
MINI REVIEWSFrom the
Unive
Financial d
Correspon
of Im
Pisana
Received J
 2011 Am
1083-8791
doi:10.101The Role of Anti-HLA Antibodies in Hematopoietic Stem
Cell Transplantation
Daniele Focosi, Alessandra Zucca, Fabrizio ScatenaDonor-specific antihuman leukocyte antigen antibodies (DSHA) have been clearly implicated in graft rejec-
tion in solid organ transplantation. Their role in allogeneic hematopoietic stem-cell transplantation (allo-
HSCT) remains unclear. We summarize here evidence supporting a role for DSHA in graft failure in animal
models of allo-HSCT and in clinical settings whenever no full HLA matching occurs.
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Donor-specific antihuman leukocyte antigen (HLA)
antibodies (DSHAs) have been implicated in graft
rejection in solid organ transplantation [1-3], but their
role in allogeneic hematopoietic stem-cell transplanta-
tion (allo-HSCT) is still under investigation. There
is some controversy as to whether DSHAs actually
mediate graft rejection, or if they are surrogate markers
for cellular immunity that causes graft failure (and that
might be overcome with more intensive T cell depletion
strategies) [4]. DSHAs cause graft failure in animal
models of allo-HSCT mainly because the cognate
HLA antigens are expressed on hematopoietic stem cells
and hematopoietic precursors [5]. HLA class I and II
antigens are not expressed on the primitive erythroid
lineage, that is, on yolk sac–derived megaloblasts circu-
lating in 5- to 6-week peripheral blood. However, they
are gradually induced on the definitive erythroid lineage
in fetal liver. Their expression on progenitors is first
detected at 6 weeks and shows a progressive increase
through 9 weeks, up to .50% of adult values [6].
HLA-DR, HLA-ABC, and glycophorin are all ex-
pressed at various stages during erythroid differentiation
[7]. Normal granulocytic progenitors, in contrast to
their mature descendents, also express HLA-DR anti-
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forming unit for granulocyte-macrophage (CFU-GM)
to the day 7 CFU-GM. The expression of HLA-DQ
antigens is instead considerably lower when using
complement-dependent cytotoxicity and can only
be detected by using more sensitive procedures
(eg, antiglobulin-augmented complement cytotoxic-
ity or immune rosette depletion). Only 50% of day
7 and 14 CFU-GM progenitor cells express detect-
ableHLA-DQ antigens, whereas a greater proportion
(80%) of the pre-CFU-GM are HLA-DQ positive
[8]. HLA-DR and HLA-DP Ags are coexpressed
on 61% of progenitor cells, predominantly those
expressing HLA-DR at high intensity [9].
Methods for Anti-HLA Antibody Testing
The complement-dependent microlymphocyto-
toxicity assay (commonly referred to as CDC), first
described by Terasaki and McClelland in 1968 [10],
was the standard internationally recognized method
for the detection of anti-HLA antibodies for 30 years.
The introduction of solid-phase assays in the 1990s
and their use as routine methods for measuring HLA
antibodies in solid organ transplant patients revolu-
tionized the field and resulted in a reassessment of
the role of both HLA class I and class II antibodies
in organ rejection and renal transplantation, in partic-
ular. There have been 2 generations of solid-phase as-
says introduced into clinical laboratories, namely, the
enzyme-linked immunosorbent assay (ELISA)-based
methods and methods using fluorescent dye impreg-
nated beads bound with HLA molecules (Luminex,
OneLambda, Canoga Park, USA). In Luminex testing,
the results are usually expressed as mean fluorescence
intensity (MFI). Although many laboratories use
MFI cutoffs around 1000-2000 to identify clinically
meaningful antibodies, there is no consensus in this1585
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studies. Cutoff variability makes comparing results
among different studies a difficult task. The introduc-
tion of these sensitive antibody detection methods into
clinical use has demonstrated that HLA antibodies are
not detectable by the CDC method, which in some
cases has been shown to have clinical relevance in
transplantation patients [3]. In addition to sensitivity,
the CDC and solid-phase assays have further differ-
ences that must be considered when interpreting and
comparing HLA antibody detection results between
techniques. For example, the CDC method detects
both immunoglobulin G (IgG) and IgM HLA and
non-HLA antibodies. In contrast, the solid-phase as-
says detect IgG and, by design, are specific for HLA
antibodies. The CDC assay by definition detects
only complement-fixing antibodies, whereas the
solid-phase assays detect both complement-fixing
and noncomplement-fixing HLA antibodies.Preliminary Evidence
In 1989, Anasetti et al. [11] reported that, in a mul-
tivariate binary logistic regression analysis, indepen-
dent risk factors associated with graft failure after
allo-HSCT were donor incompatibility for HLA-B
and DR (relative risk5 2.1) and a positive CDC cross-
match for antidonor lymphocytotoxic antibody (rela-
tive risk 5 2.3). Residual host lymphocytes were
detected in 11 of 14 patients with graft failure, suggest-
ing that the mechanism for graft failure could be host-
mediated immune rejection. In 2010, Mattsson et al.
reported that only 1 of 11 patients with allo-HSCT re-
jection was positive in a T cell CDC crossmatch before
allo-HSCT and 4 of 11 in B-cell CDC crossmatches
[12]. These poor predictive values are likely because of
the fact that even low- or intermediate-titer DSHAs,
which fail to cause a positive CDC crossmatch (but
can be detected by Luminex testing), can be enough to
cause allo-HSCT rejection.
Xu et al. [13,14] reported in 2006 that T cell
targeted conditioning regimens (eg, monoclonal
antibodies targeting CD8, T cell receptor, or
CD154) could not enhance engraftment in sensitized
mice, and that sensitization could be transferred by
donor-specific antibodies in serum. Taylor et al. [15]
further showed in 2007 that whereas allosensitization
resulted in the priming of both cellular and humoral
immunity, preformed antibody was the major barrier
to engraftment. The generation of crossreactive allo-
antibodies led to rejection of a different MHC-
disparate strain. Imaging studies in HSCT using green
fluorescent protein (GFP)-positive bone marrow cells
indicated that antibody-mediated rejection (dependent
upon host FcR1 cells) was very rapid (\3 hours) in
primed recipients, whereas T cell–mediated rejection
in nonprimed mice took more than 6 days. HSCsincubated with serum from primed mice were elimi-
nated in nonprimed recipients, indicating that persis-
tent exposure to a high-titer antibody was not
essential for rejection. High donor engraftment was
achieved in a proportion of primed mice by mega-
HSC dose, in vivo T cell depletion, and high-dose
immunoglobulin infusion [15].
Anti-HLA Ab in Partially HLA-Matched HSCT
Spellman et al. [16] tested archived pretransplan-
tation sera from graft failure patients (n 5 37) and
a matched case-control cohort (n 5 78) to evaluate
the role of DSHAs in unrelated donor HSCT. Among
the 37 failed transplantations, 9 (24%) recipients pos-
sessed DSHAs (MFI . 2000) against HLA-A, B,
and/or DP, compared with only 1 (1%) of 78 controls.
Therefore, the presence of DSHAs was significantly
associated with graft failure (odds ratio 5 22.84; 95%
confidence interval, 3.57-infinity; P\ .001), indicating
that the presence of pretransplantation DSHAs in
recipients of unrelated donorHSCT should be consid-
ered in donor selection.
Anti-HLA Ab in Haploidentical HSCT
To address the hypothesis that the presence of
DSHA contributes to the development graft failure
in haploidentical HSCT, Ciurea et al. [17] tested 24
consecutive patients for the presence of anti-HLA an-
tibodies by Luminex. The study included a total of 28
haploidentical transplants, each with 2 to 5 HLA allele
mismatches in A, B, C, DRB1, andDQB1 loci, at a sin-
gle institution, from September 2005 to August 2008.
DSHAs (MFI . 500) were detected in 5 patients
(21%) at baseline. One of them was successfully
desensitized with rituximab and plasma exchange
(no detectable DSHA before transplantation) and
engrafted. One patient with DSHA did not undergo
desensitization, and the remaining 3 patients were
not successfully desensitized despite rituximab and
plasma exchange: 3 of these 4 (75%) failed to engraft,
compared with 1 of 20 (5%) without DSHAs
(P5 .008).Noother known factors that could negatively
influence engraftment were associated with the develop-
ment of graft failure in these patients. These results sug-
gest that DSHAs are associated with a high rate of graft
rejection in patients undergoing haploidentical HSCT.
In another study using Luminex, Leffell et al.
[18] found that among the haploidentical HSCT
recipients, 15.7% (8 of 51) developed de novo DSHAs
(MFI . 1000) after transplantation, and 29.4% also
had antibodies directed toward third-party HLA anti-
gens. Among the DSHA, 9.8% were directed toward
HLA class I antigens; 7.8% were against class II anti-
gens; and 2.0% had both class I and II specificity. The
relative strength of posttransplantation antibodies
was low, with no significant difference in the mean
Biol Blood Marrow Transplant 17:1585-1588, 2011 1587Anti-HLA Antibodies in HSCTmaximumMFI values between third-party andDSHAs.
Because only a small number (10.2%) of the posttrans-
plantation samples were obtained 180 days or more
post-HCT, longer-term study is needed to evaluate
any clinical relevance of these low-to-moderate levels
of donor-specific antibody in 1 haplotype-mismatched
recipient, as well as to determine whether any other
antibodies occur at later times [18].
Whenever there are no alternative donors, IgG im-
munoadsorption onto staphylococcal protein A (which
removes from serum all human IgGs independently
from their antigen specificities) has provided successful
engraftment in case reports when a positive flow cy-
tometry crossmatch had been documented [19]. An-
other successful approach to avoid graft rejection in
patients who have DSHAs has used a combination of
donor platelet transfusion, a mega-dose infusion of
HSCs, and rituximab [20].Anti-HLA Ab in Umbilical Cord Blood HSCT
In cord blood transplantation (CBT), DSHAs may
be particularly relevant because patients are often mark-
edly mismatched to donors, and limited donor cells
preclude crossmatching. The recent development of
solid-phase assays allows characterization of host allor-
eactivity to individual HLA antigens with sufficient sen-
sitivity and specificity to allow consideration of ‘‘virtual
crossmatch’’ testing (ie, matching of anti-HLA anti-
bodies and donor HLA typing in order to identify
DSHAs) as a surrogate for conventional crossmatch test-
ing in the CBT setting [21]. Gutman et al. [22] reported
that among 46 consecutive patients, 4 patients (9%) had
evidence of at least moderate DSHA (MFI . 4000) to
antigens on cord units originally selected for transplan-
tation. Takanashi et al. [23] retrospectively performed
testing for anti-HLA antibody with Luminex at the
Japanese Red Cross Tokyo Blood Center. Among 386
CBTs, which were first myeloablative HSCT for malig-
nancies and used a single unit of cord blood, 89 tested
positive (MFI . 800). Among the antibody-positive
group, the cord blood did not have the corresponding
HLA type for the antibody in 69 cases (‘‘Ab-positive’’),
whereas 20 cases had DSHA (‘‘positive-versus-CB’’).
Cumulative incidence of neutrophil recovery 60
days posttransplantation was 83% (95% confidence
interval, 79%-87%) for the antibody-negative group
(‘‘Ab-negative’’), 73% for ‘‘Ab-positive,’’ but only 32%
for the DSHA group (P \ .0001). With multivariate
analysis, the DSHA group had significantly lower neu-
trophil recovery (relative risk [RR] 5 0.23) and platelet
recovery (RR 5 0.31) than the ‘‘Ab-negative.’’ These
findings recommend that, as often as possible, cord
units should be changed to avoid sensitized mis-
matches [22,24]. Moreover, there are CBT cases of
engraftment despite DSHAs, suggesting the
importance of cell dose [25].CONCLUSIONS
The number of HLA-mismatched transplanta-
tions has been rising in the present era. On the basis
of the previously mentioned findings, Luminex test-
ing for anti-HLA antibodies should be performed in all
HSCT settings where HLAmatching is not complete,
independently from the amount of loci considered.
Given the large benefit of such donor screening (expe-
cially in the setting of cord blood and haploidentical
HSCT), the benefit-to-cost ratio is expected to be
very high. Immunoadsorption and plasmapheresis
(and rituximab) could be considered to desensitize
the recipient when no alternative donor is available.ACKNOWLEDGMENTS
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